Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Covington
Novartis
McKesson
Mallinckrodt
Baxter
Cipla
Federal Trade Commission
Medtronic
Chinese Patent Office

Generated: February 22, 2018

DrugPatentWatch Database Preview

Regadenoson - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for regadenoson and what is the scope of regadenoson freedom to operate?

Regadenoson
is the generic ingredient in one branded drug marketed by Astellas and is included in one NDA. There are seventeen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Regadenoson has eighty-four patent family members in twenty-six countries.

There are eight drug master file entries for regadenoson. One supplier is listed for this compound.
Summary for regadenoson
International Patents:84
US Patents:17
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 8
Suppliers / Packagers: 1
Bulk Api Vendors: 34
Clinical Trials: 52
Patent Applications: 76
Drug Prices:see low prices
DailyMed Link:regadenoson at DailyMed
Pharmacology for regadenoson

US Patents and Regulatory Information for regadenoson

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for regadenoson

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,163,057 Methods of myocardial perfusion imaging ➤ Try a Free Trial
8,278,435 N-pyrazole A2A receptor agonists ➤ Try a Free Trial
8,268,988 Process for preparing an A2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
7,956,179 Process for preparing an A2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
7,732,595 Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
8,524,883 Monohydrate of (1-{9-[4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide ➤ Try a Free Trial
8,569,260 N-pyrazole A.sub.2A receptor agonists ➤ Try a Free Trial
8,906,878 Myocardial perfusion imaging methods and compositions ➤ Try a Free Trial
8,071,566 Methods of coronary imaging ➤ Try a Free Trial
7,671,192 Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for regadenoson

Supplementary Protection Certificates for regadenoson

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C004/2011 Ireland ➤ Try a Free Trial SPC004/2011: 20110719, EXPIRES: 20250620
00477 Netherlands ➤ Try a Free Trial PRODUCT NAME: REGADENOSON ALSMEDE FARMACEUTISCHE AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
2 Finland ➤ Try a Free Trial
C0004 France ➤ Try a Free Trial PRODUCT NAME: REGADENOSON ET SES SELS; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
C/GB11/005 United Kingdom ➤ Try a Free Trial PRODUCT NAME: REGADENOSON; REGISTERED: UK EU/1/10/643/001 20100906
2011 00005 Denmark ➤ Try a Free Trial PRODUCT NAME: REGADENOSON OG SALTE DERAF
2011 Austria ➤ Try a Free Trial PRODUCT NAME: REGADENOSON UND DESSEN SALZE; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
90003-2.L Sweden ➤ Try a Free Trial PRODUCT NAME: REGADENOSON OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/643/001 20100906
2011000010 Germany ➤ Try a Free Trial PRODUCT NAME: REGADENOSON UND DIE SALZE DAVON; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
785 Luxembourg ➤ Try a Free Trial 91785, EXPIRES: 20250621
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Citi
Express Scripts
AstraZeneca
Cantor Fitzgerald
UBS
Covington
Chubb
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot